Federal Circuit Affirms: Biologics For Neutropenia Treatment Do Not Infringe

(November 13, 2017, 1:48 PM EST) -- WASHINGTON, D.C. — A Florida federal judge did not err in rejecting allegations by Amgen Inc. and Amgen Manufacturing Limited (Amgen, collectively) that proposed biosimilar versions of two Amgen pegfilgrastim and...

To view the full article, register now.